---
title: "Kura Oncology updates CEO Troy Wilson severance terms in revised employment agreement"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294265229.md"
description: "Kura Oncology revised executive employment agreements for CEO Troy Wilson, CCO Brian Powl, and COO Kathleen Ford in July 2026. Severance terms increase significantly during corporate transaction windows: Wilson receives 24 months' salary and 200% bonus; Powl and Ford receive 18 months' salary and 150% bonus, with equity acceleration. Outside such windows, standard severance applies."
datetime: "2026-07-29T21:27:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294265229.md)
  - [en](https://longbridge.com/en/news/294265229.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294265229.md)
---

# Kura Oncology updates CEO Troy Wilson severance terms in revised employment agreement

-   Kura Oncology revised executive employment agreements for CEO Troy Wilson on July 24, 2026, then for CCO Brian Powl, COO Kathleen Ford on July 27. \* Outside a corporate transaction window, severance shifts to 12 months base salary, up to 12 months COBRA premiums, option exercise period up to 12 months. \* Within 59 days before through 18 months post corporate transaction close, Wilson severance becomes 24 months salary, 200% target bonus, equity acceleration. \* In the same window, Powl and Ford severance becomes 18 months salary, 150% target bonus, equity acceleration. \* COBRA premium coverage extends to 24 months for Wilson, 18 months for Powl and Ford in corporate transaction-related terminations. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-324202), on July 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [KURA.US](https://longbridge.com/en/quote/KURA.US.md)

## Related News & Research

- [Kura Oncology posts investor presentation on darlifarnib plus cabozantinib clinical update in renal cell carcinoma](https://longbridge.com/en/news/293940059.md)
- [Kura Oncology reports up to 50% response rate for darlifarnib-cabozantinib combo in Phase 1a kidney cancer trial](https://longbridge.com/en/news/293917050.md)
- [Heritage Financial EVP Chief Banking Officer Kelli Ann Wilson sells 3,778 common shares for $112,182.05](https://longbridge.com/en/news/294419067.md)
- [Kura Oncology Reports 50% Response Rate in RCC Combination Study](https://longbridge.com/en/news/293955319.md)
- [General Fusion leadership team to join Canaccord Genuity Growth Conference fireside chat](https://longbridge.com/en/news/294414129.md)